18. Initial results of neoadjuvant chemoradiation followed by consolidation chemotherapy pre-operative in stage II, III rectal cancer patients
Main Article Content
Abstract
The prospective study evaluated the initial results of neoadjuvant chemoradiation followed by consolidation chemotherapy (total neoadjuvant therapy) in stage II, III rectal cancer patients. 73 patients with stage II and III rectal cancer at 108 Military central hospital and Nghe An Oncology hospital from April 2022 to November 2023 received preoperative chemoradiation of 50.4 Gy concurrent with Capecitabine 825mg/m2, twice a day x 5 days/week; neoadjuvant chemotherapy with FOLFOX or CAPEOX was added then followed by surgery. The mean age was 60.1 ± 10.5 years old, with a male/female ratio of 1.43/1. Stage II and III were 12.3% and 87.7% respectively. After treatment, 69.9% of patients had reduction in the tumor stage and 82.2% of patients had reduction in the lymph node stage. 30.1 % of patients had pathological complete response (pCR). Overall sphincter prevention rate was 75.3%, with low rectal cancer reached 46.7%. Side effects were mainly at grade 1.2.
Article Details
Keywords
Rectal cancer, pathological complete response (pCR), total neoadjuvant therapy (TNT)
References
2. Glynne-Jones R, Wyrwicz L, Tiret E et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28: iv22–iv40.
3. Nahas SC, Rizkallah Nahas CS, Sparapan Marques CF, et al. Pathologic complete response in rectal cancer: can we detect it? Lessons learned from a proposed randomized trial of watch-and-wait treatment of rectal cancer. Abdom Radiol (NY). 2016; 59(4): 255-263.
4. Fokas E, MD, DPhil, Allgauer M, et al. Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. Journal of Clinical Oncology. 2019; Volume 37, Number 34.
5. Van der Valk MJM, Marijnen CAM, Van Etten B et al. Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial. Radiother Oncol. 2020; 147: 75-83.
6. Conroy T, Lamfichekh N, Etienne PL et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial. J Clin Oncol. 2020; 38(suppl): 4007a.
7. Benson AB, Venook AP, Al-Hawary MM, et al.Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncolog. J Natl Compr Canc Netw. 2022; 20(10): 1139-1167. doi: 10.6004/jnccn.2022.005.
8. Edge SB, Byrd DR, Compton CC, et al, 3rd. AJCC cancer staging manual. 7th ed. New York: Springer-Verlag. 2010.
9. Phạm Khánh Toàn, Võ Văn Xuân. Đánh giá kết quả hóa xạ trị tiền phẫu ung thư trực tràng bằng kỹ thuật VMAT kết hợp Capecitabin đường uống tại bệnh viện K. Tạp chí Y học Việt Nam.2021; số 1-2021: tr. 261-266.
10. Liu S, Jiang, Xiao et al. Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis. Oncologist. 2021; 26(9): e1555-e1566.
11. Nguyễn Minh Hành, Huỳnh Thanh Tuệ, Phạm Nguyên Tường, và cs. Đánh giá kết quả hóa-xạ trị tiền phẫu và phẫu thuật ung thư trực tràng tiến triển tại chỗ. Tạp chí Y Dược lâm sàng.2022; 108; số 5/2023: tr. 36-42.
12. Garcia-Aguilar, Oliver S Chow, David D Smith, et al(2015). Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015; August; 16(8): 957–966.